Third Rock Ventures Sells $17.2 Million in Rapport Therapeutics Shares Amid Stock Surge
Third Rock Ventures, a major shareholder of Rapport Therapeutics, sold 426,005 shares for $17.18 million on April 17, 2026, representing 5.3% of its direct holdings. The stock has surged 230% over the past year, and Phase 3 trials are nearing completion. The sale may signal insider activity amid rising stock prices.
Topics: insider trading Rapport Therapeutics SEC filings stock ownership